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INTRODUCTION
The inflammatory myopathies (IM) are a heterogeneous
group of disorders characterized by chronic inflammation of
striated muscles (polymyositis) and sometimes skin (dermato-
myositis). Polymyositis can be further divided into several sub-
groups. Patients with IM of any category may have autoanti-
bodies. Antibodies against aminoacyl-tRNA synthetase (anti-
synthetase antibodies) among these autoantibodies are known
to be highly specific for IM. Anti-Jo-1 antibody is the most
frequently identified antibody of the group of antisynthetases,
and is detected more commonly in polymyositis than in der-
matomyositis (1, 2). The onset of illness having this antibody
is often rapid, with any combination of symptoms, including
fever, polyarthritis, inflammatory myositis, Raynaud’ s phe-
nomenon,  “mechanic’ s hands” , and interstitial lung disease
(ILD) (1).
Myositis patients with anti-Jo-1 antibody have a poor prog-
nosis and frequent relapses. These patients initially respond
well to corticosteroids, but often relapse during tapering of
the agent, and thus immunosuppressive agents such as aza-
thioprine, methotrexate, and cyclophosphamide are frequent-
ly needed to control the disease (3). Despite aggressive im-
munosuppressive treatment, some patients could die of the
progressive disease (4). Methotrexate and azathioprine have
been widely used with corticosteroids for those patients, and
the efficacy of combination of these two agents was reported
(5). In addition, the therapeutic effects of cyclosporine have
been described in treatment-resistant myositis. Although the
combined use of cyclosporine and methotrexate in refracto-
ry polymyositis was reported to be successful (6), it has not
been described in refractory subgroup of patients with anti-
Jo-1 antibody. We report a 32-yr-old female patient with poly-
myositis and anti-Jo-1 antibody. The disease was initially re-
fractory to multiple immunosuppressive agents, but it was
eventually controlled by combination treatment of cyclosporine
and methotrexate.
CASE REPORT
In March 2000, a 32-yr-old woman was admitted with a
one-month history of polyarthralgia and shortness of breath
on exertion. She had not had weight loss, fever, alopecia, oral
ulcer, or Raynaud’ s phenomenon. There was no past history
of specific drug ingestion, smoking, abuse of alcohol, or envi-
ronmental toxin exposure. On physical examination, inspi-
ratory crackles were heard on both lower lung fields, and heart
sounds were normal. An inflammatory polyarthritis affecting
small joints of both hands and both knees was noted. Her fin-
gers were those of the  “mechanic’ s hands” . However, the prox-
imal muscle weakness and tenderness were absent. 
Initial laboratory studies showed elevated levels of muscle
enzymes, including creatinine kinase (CK) 1,895 U/L (normal
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<250 U/L) and lactate dehydrogenase 735 U/L (normal<420
U/L). The erythrocyte sedimentation rate was 20 mm/hr, and
the C-reactive protein level was 1.89 mg/dL. The rheumatoid
factor was negative and the antinuclear antibody titer was 1:
320 with a cytoplasmic pattern. Anti-Jo-1 antibody was pos-
itive. There were no specific abnormal data on other chemistry
profiles and immunological studies. A chest radiograph reveal-
ed bibasilar reticular changes consistent with ILD (Fig. 1A).
High resolution CT scan showed reticular interstitial infil-
trates with ground-glass opacities suggesting an active inflam-
mation. Pulmonary function test revealed a mixed restrictive
and obstructive pattern with a forced vital capacity of 56%
of predicted, forced expiratory volume in 1 second of 57% of
predicted, and carbon monoxide diffusing capacity of 64% of
predicted. Bronchoalveolar lavage showed 12% neutrophils,
38% lymphocytes, and 50% macrophages. Transbronchial
lung biopsy could not be performed due to dyspnea. Cultures
for bacteria, fungus, and mycobacteria were negative. There
was no evidence of myositis on the magnetic resonance imag-
ing (MRI) of both thighs (Fig. 2A), or on electromyographic
examination of the extremities.
The diagnosis of antisynthetase syndrome with subclinical
myositis was established. On day 5 of hospitalization, dyspnea
was suddenly aggravated. Tachypnea and high fever were de-
veloped. The arterial blood gas analysis without O2supplemen-
tation showed PaCO2 of 24.2 mmHg, PaO2 of 69.7 mmHg,
and O2 saturation of 93.2%. Extensive pulmonary consolida-
tions and permeability-type pulmonary edema resembling
Fig. 1. Initial chest radiograph shows fine reticular opacities at
both lower lung bases (A). Follow-up radiograph obtained on the
fifth admission day shows extensive consolidations of both lower
lung zones and alveolar consolidations of parahilar areas sug-
gesting a permeability-type pulmonary edema (B). The consoli-
dation was resolved after methylprednisolone intravenous pulse
therapy (C).
A
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acute respiratory distress syndrome (ARDS) were noted on the
chest radiograph (Fig. 1B). Her symptoms of dyspnea, fever,
and polyarthralgia were subsided with intravenous (IV) pulse
methylprednisolone (500 mg/day for 3 consecutive days). Sub-
sequently, monthly IV pulse cyclophosphamide (500 mg/m
2)
and prednisolone 1 mg/kg/day (50 mg/day) were started. Aza-
thioprine 1 mg/kg/day (50 mg/day) was added. The pulmo-
nary consolidations on the previous chest radiograph were al-
most cleared (Fig. 1C), and the CK level was decreased to 512
U/L.
In the late April 2000, she noted the difficulty in raising
both arms, and in climbing stairs, when prednisolone was tap-
ered to 35 mg/day. The CK level was increased to 6,090 U/L.
The findings of the follow-up MRI of both thighs (Fig. 2B)
and the muscle needle biopsy specimen were consistent with
inflammatory myositis. The prednisolone and azathioprine
were increased to 50 mg daily and 75 mg daily, respectively.
The monthly IV cyclophosphamide pulse therapy was con-
tinued. One month later, the muscle weakness was not improv-
ed, and the CK level did not decrease below 4,000 U/L. Fur-
thermore, on the next month, a life-threatening sepsis occurr-
ed, which was successfully treated.
In the early July 2000, prednisolone 30 mg/day and cyclo-
sporine 4 mg/kg/day (200 mg/day) instead of cyclophospha-
mide and azathioprine were prescribed. During the next four
months, in spite of these medications, the CK level did not
decrease below 4,000 U/L, with a persistent muscle weakness.
In November 2000, methotrexate 10 mg/week was added
to cyclosporine, and gradually increased to 17.5 mg/week.
After 2 months, the CK level was decreased below 1,000 U/L,
and the muscle strength gradually began to improve. Pred-
nisolone could be reduced to 15 mg/day. In March 2001, the
level of muscle enzymes was in the normal range (CK 55 U/L,
LDH 334 U/L), and the muscle strength was gradually restor-
ed. Prednisolone was successfully tapered to 5 mg/day. The
follow-up chest radiograph and pulmonary function test were
almost returned to normal.
DISCUSSION
Myositis patients with any of antisynthetase antibodies have
a high frequency of ILD. Several other clinical features besides
lung involvement and inflammatory myositis are more com-
mon in myositis patients with antisynthetases, including fever,
inflammatory polyarthritis, Raynaud’ s phenomenon, and  “me-
chanic’ s hands” . This disease entity is referred to as the “anti-
synthetase syndrome” (1, 7). In our case that the diagnosis
of antisynthetase syndrome with anti-Jo-1 antibody was made,
the lung involvement resembling ARDS initially occurred,
and the findings suggestive of clinically overt myositis were
absent except the elevation of muscle enzymes. Subsequent-
ly, she developed an overt myositis during the tapering of pre-
dnisolone.
Even though corticosteroids remain the agent of choice
for the initial treatment of IM, their use causes many adverse
effects. The immunosuppressive agents such as azathioprine,
methotrexate, cyclophosphamide, or cyclosporine have been
increasingly used with corticosteroids in patients with rapid-
ly progressive illness having serious extramuscular manifes-
tations, disease relapses with the reduction of corticosteroids,
serious corticosteroids-related complications, or the disease
refractory to corticosteroids only (3). Because the prognosis
of patients with IM relies on early diagnosis and treatment
(8), the concomitant use of such agents with corticosteroids
may be considered at an early stage of the disease.
Interstitial pneumonitis is a serious complication of IM, and
considerably influences the patient’ s prognosis. Once fibro-
sis is established, the disease is resistant to treatment. So im-
munosuppressive agents are necessary when the inflammat-
ory, ground-glass phase predominates (3). A prospective trial
of IV pulse cyclophosphamide was effective in six patients with
Fig. 2. There were no significant muscular signal abnormalities on the initial T2-weighted, magnetic resonance imaging of both thighs
performed on admission (A). Follow-up scanning of the same locations shows bilateral symmetric, high signal intensity of thigh muscles
except for adductor muscle groups suggestive of inflammatory myositis (B).
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rapidly progressive ILD including 2 patients with polymyositis
(9). The efficacy of cyclosporine in IM has been described in
progressive ILD (4, 10) as well as in the primary muscle in-
volvement. In addition, Tellus et al. reported a patient with
anti-Jo-1 positive refractory polymyositis and ILD who was
successfully treated with cyclosporine (11).
The rapidly progressive lung disease of our patient was effec-
tively treated with methylprednisolone pulse therapy and im-
munosuppressive agents, and her lung disease has been sta-
ble until now. However, the overt myositis occurred during
the tapering of prednisolone. The muscle weakness and the
elevation of muscle enzymes were refractory to the high-dose
prednisolone and several immunosuppressive agents such as
azathioprine, cyclophosphamide, and cyclosporine. Beneficial
effects of methotrexate have been reported in patients with
IM (8), but this agent was initially avoided as treatment reg-
imen because of its potential pulmonary toxicity in the case
with preexisting lung disease. After all, the muscle strength
and muscle enzyme levels were restored when methotrexate
was cautiously added to cyclosporine. Mitsunaka et al. report-
ed on the successful combined use of cyclosporine and metho-
trexate in a patient with treatment-resistant polymyositis, in
whom anti-Jo-1 antibody was negative (6). The combined
use of these two agents in refractory myositis with anti-Jo-1
antibody has not to our knowledge yet been described.
The combination therapy with cyclosporine and methotrex-
ate in severe rheumatoid arthritis has been proven effective
and relatively well tolerated (12, 13). In addition, this com-
bination therapy seemed to be effective and also well tolerat-
ed in refractory juvenile rheumatoid arthritis and juvenile
dermatomyositis (14). To date, the experience of such a treat-
ment in refractory myositis is very limited, and the combined
treatment of cyclosporine and methotrexate should be urgent-
ly considered for future studies.
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